Research Paper Volume 14, Issue 9 pp 3826—3835
Menstrual blood-derived stem cells and its mitochondrial treatment improve the ovarian condition of aged mice
- 1 Medical School of Chinese PLA, Department of Obstetrics and Gynecology, The First Medical Center of PLA General Hospital, Beijing 100853, China
- 2 Department of Transformation Medicine Center, The Medical Innovation Research Division of Chinese PLA General Hospital, Beijing 100853, China
- 3 Senior Department of Obstetrics and Gynecology, The Seventh Medical Center of PLA General Hospital, Beijing 100853, China
- 4 Key Laboratory of RNA Biology, Center for Big Data Research in Health, Institute of Biophysics, Chinese Academy of Sciences, Beijing 100101, China
- 5 Department of Clinical Biobank Center, The Medical Innovation Research Division of PLA General Hospital, Beijing 100853, China
Received: September 13, 2021 Accepted: April 22, 2022 Published: May 3, 2022https://doi.org/10.18632/aging.204043
How to Cite
Copyright: © 2022 Zhang et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Aging causes a decline in ovarian function and may contribute to ovarian failure and infertility. We investigated the effect of menstrual blood-derived mesenchymal stem cells (MenSCs) and their mitochondria on ovarian function in aged mice. We performed two treatment protocols: i) ovaries of recipient aged mice were treated in vivo with MenSCs 3D alginate gel; ii) ovaries were injected with mitochondria suspension and then incubated with mitochondrial 3D gel. Seven days after treatment, ovaries were harvested for histological assessment by HE staining and transcriptomic analysis by RNA-seq. Our data showed that after incubation with stem cell 3D gel, the MenSCs could be detected in the recipient mouse ovary. HE staining showed that the follicular state of aging ovary improved with both treatments. RNA-seq analysis showed that mitochondrial pathway-related genes were upregulated and significantly enriched in the ovaries treated by MenSCs or their mitochondria.
Conclusions: Treatment with MenSCs or their mitochondria can enhance the expression of mitochondrial pathway-related genes and promote the recovery of ovarian function in aged mice.
Ovary, the center of female fertility regulation, is one of the most rapidly aging organs [1, 2]. Aging is accompanied with a decrease in the number and quality of follicles in the ovary; however, the mechanism is still unclear. It may be associated with the acceleration of follicular atresia and the shrinking of the primordial follicle pool [3, 4]. Decreased ovarian reserve (DOR) refers to the decrease in the number of recruitable follicles in the ovaries and decreased quality of the eggs. DOR leads to insufficient secretion or absence of sex hormones and decreased fertility, which can progressively worsen into ovarian failure . Clinically, DOR is characterized by a decrease in anti-Mullerian hormone (AMH) levels, the number of antral follicles (AFC), and elevated basic follicle-stimulating hormone (FSH) levels . The incidence and development of DOR accelerates significantly with aging. Currently, ovarian function is restored mainly through hormone therapy and immunotherapy. However, the effects of these treatments are transient and one-off and cannot effectively promote the regeneration and repair of self-damaged ovarian tissue. In view of these limitations of conventional treatment methods, scientists are actively looking for new and effective alternatives [7, 8].
Stem cells have been studied for the treatment of premature ovarian failure (POF) [9, 10]. Mesenchymal stem cells (MSCs) treatment technology is an important branch of stem cell therapy, which is considered to be a new hope for organ damage repair in the future . Menstrual blood-derived mesenchymal stem cells (MenSCs) are a recently discovered type of pluripotent stem cells, that reside the endometrium and continuously renew themselves with the menstrual cycle. MenSCs can be isolated directly from menstrual blood in a non-invasive way, avoiding ethical disputes, and thus constitute an easily accessible source of stem cells, that is renewed periodically [12, 13]. MenSCs highly express mesenchymal stem cell surface markers, exhibit stronger proliferative ability than bone marrow derived stem cells and have been confirmed to have multidirectional differentiation potential . MenSCs can be induced to differentiate into cell lineages such as chondrocytes, adipocytes, osteoblasts, neural cell lines, cardiomyocytes, while maintaining high proliferative ability even after continuous passages for multiple generations. They also express and secrete a variety of cytokines such as VEGF, FGF, KGF and HGF; at the same time, exhibit low immunity, tumorigenicity, and immunosuppressive characteristics [14, 15].
The mitochondria, where cells carry out aerobic respiration, are associated with age-related decrease in female reproductive outcome [16, 17]. Ovarian granulosa cells are rich in mitochondria, which metabolize cytoplasmic glucose into pyruvate and transport it to oocytes to produce ATP and maintain their development . The morphology of mitochondria in granulosa cells changes with age, accompanied by a significant decrease in the mitochondrial membrane potential and ATP synthesis. Apoptosis of granulosa cells increases with age, which may affect oocyte function or cause changes in the ovarian reserve .
In this study, we prepared and used mitochondrial suspension, mitochondrial 3D gel, and stem cell 3D gel derived from mouse MenSCs, to treat the ovaries of aged mice. We examined the availability and feasibility of MenSCs and their mitochondria in the treatment of ovarian aging. We further explored the possible mechanism by which MenSCs and their mitochondria repair ovarian dysfunction.
Macroscopic ovarian sizes of the recipient mice treated by MenSCs and mitochondria
Ovaries of aged recipient CD-1 (ICR) mice (10–12 months old) were treated with, either MenSCs 3D gel (MO-MenSCs) incubation or mitochondrial injection combined with mitochondrial 3D gel (MO-MITO) incubation. After 7 days following the treatment, ovaries were dissected from the recipient mice and their overall morphology and size was examined. The blank gel control group and MO-MITO treatment group had comparable ovarian volume. However, the MO-MenSCs treatment group had higher ovary size and volume compared to control group. (Figure 1A, 1B).
Morphological changes in the recipient ovaries treated by MenSCs and mitochondria
We further observed the histomorphology of the recipient ovaries by Hematoxylin-eosin (HE) staining. HE staining showed that the ovaries of 2–3 months young control group (MY-Control) were properly structured, with different stages of developing follicles, and layers of granulosa cells around the secondary follicle (Figure 2A). The aged control mice (MO-Control) showed disordered ovarian structure, with fewer number of growing follicles at each stage and granulosa cells as well (Figure 2A). MO-control ovaries had more atretic follicles, and enlarged intercellular space. MO-MenSCs and MO-MITO treatment moderately improved the morphology of aged ovaries (Figure 2A). The number of growing follicles at each stage and corpus lutea were counted in the MO-control, MO-MenSCs, and MO-MITO treatment groups. MO-MenSCs and MO-MITO treatment groups showed moderately higher number of primary and secondary follicles compared to the MO-control group (Figure 2B).
Tracking donor MenSCs in the ovaries of recipient mice
We labelled donor MenSCs with red fluorescent CM-Dil and tracked them in the recipient mouse ovaries 7 days after treatment with MenSCs 3D gel. The ovaries from recipient mice were harvested after sacrifice, and paraffin sections were prepared to visualize the location of labelled MenSCs. CM-Dil red labelled MenSCs were clearly visible inside the recipient ovaries 7 days after treatment with 3D MenSCs gel (Figure 3). This result indicates that MenSCs can migrate into aged ovaries in vivo, which may repair the injury and improve the ovarian condition in aged mice.
RNA expression analysis and related gene functions and pathways
Furthermore, to link ovary morphology changes and altered gene expression, RNA sequencing (RNA-seq) was performed to analyze the global transcriptomic profiles from MO-control and MO-MenSCs and MO-MITO treated ovaries. A sizable number of genes (429 upregulated and 677 downregulated) showed at least two-fold differential expression between MO-MenSCs and MO-control samples (Figure 4A). These differentially upregulated expressed genes were significantly enriched in cellular component (CC) categories related to proteinaceous extracellular matrix, extracellular matrix, collagen trimer, basement membrane, extracellular exosome, nucleoplasm, cytoplasm, mitochondrial respiratory chain complex I, growth cone, mitochondrial intermembrane space, mitochondrion, and mitochondrial inner membrane (Figure 5A).
Figure 4. Identification differently expressed genes by RNA-seq analysis. Volcano plots showing differently expressed genes between MO-MenSCs vs. MO-control (A) and MO-MITO vs. MO-control (B) samples identified using transcriptomic data at day 7. Red dots denote the genes passing our p value and fold difference thresholds. The genes gene names of significant genes are marked. Venn diagram depicting the overlap of up-regulated genes between MO-MenSCs vs. MO-control and MO-MITO vs. MO-control comparisons (C).
Figure 5. Functional annotation of up-regulated genes between MO-MenSCs vs. control (A) and MO-MITO vs. control samples (B).
Similarly, a total of 1,969 genes were upregulated and 2,322 genes were downregulated with at least two-fold change in MO-MITO samples compared to MO-control samples (Figure 4B). Of the genes that were upregulated in MO-MenSCs group, nearly 30% of them were also upregulated in MO-MITO group (Figure 4C). Significant enrichment of these 1,969 upregulated genes was observed in the following cellular components: ribosome, intracellular ribonucleoprotein complex, mitochondrion, mitochondrial respiratory chain complex I, respiratory chain, mitochondrial inner membrane, catalytic step 2 spliceosome, centrosome, spindle, and mitochondrial ribosome (Figure 5B). Interestingly the differentially expressed genes in both treatments were significantly enriched in mitochondria and their components (Figure 5A, 5B). This suggests that treatment of aged ovaries with MenSCs or their mitochondria may affect mitochondria related pathways.
We also found that several genes involved in mitochondrial pathways were upregulated upon MO-MenSCs or MO-MITO treatment in aged ovaries. Genes involved in mitochondrial ATP synthesis such as mt-Atp8, mt-Co2, mt-Nd3, mt-Nd4l, Got2-ps1, Tomm7, mt-Atp6, mt-Tl2, Atp5k, mt-Te, and NADH dehydrogenase were significantly upregulated in the MO-MenSCs treatment group compared to MO-control group (Figure 6A). Similarly, in the MO-MITO treatment group, mt-Nd1, Immp2l, Mrpl39, mt-Ti, Mrpl45, Slc25a29, Slc25a14, Mrpl48-ps, Ucp3, Mrps17, Tomm20 and other mitochondrial-related genes were upregulated, whereas the autophagy pathway molecule Prkn was significantly down-regulated compared to the MO-control group (Figure 6).
Female fertility decreases significantly after 37 years and begins to fade after 45 years of age in humans. Histological analysis of the ovaries of 40–48 weeks old mice showed significantly reduced number of follicles at different stages, and increased number of atretic follicles. These results suggest that 40–48 weeks (10–12 months) old mice could represent women of age over 38 years old and can be used to study ovarian aging.
Mitochondria play a significant role in the complex process of oocyte development. In addition to supplying energy for granulosa cell proliferation and oocyte development, mitochondria can also regulate important physiological processes such as antioxidant defense and apoptosis of granulosa cells. Additionally, mitochondria maintain the structural integrity of granulosa cells, their function, and prevent the damage caused by mutations. A study on mouse oocytes revealed an age-associated alteration of gene expression patterns including the genes involved in mitochondrial functions and oxidative stress . The quality of oocytes is a key factor affecting the outcome of pregnancy. The quality of oocytes declines with ovarian ageing, leading to a decline in female fertility. Our transcriptomic analysis revealed that treatment with MenSCs upregulated the expression of several mitochondrial genes involved in ATP synthesis, along with NADH dehydrogenase indicating that they promote mitochondrial ATP synthesis in aging ovary. It is known that insufficiency in cell energetics due to low mitochondrial ATP synthesis could cause chromosomal aberrations and could affect oocyte number and embryo health. Aging is associated with reduced mitochondrial function in granulosa cells . Interestingly, ATP6 and ATP8 genes encoding two subunits of the ATP synthase complex (complex V of the respiratory chain) itself, were among the ovarian genes that were upregulated upon treatment with MenSCs. Thus, MenSCs could restore the function of aging ovaries and improve oocyte quality by promoting mitochondrial ATP synthesis which is reflected in our RNA-seq data [22–25].
To summarize, we treated the ovaries of aged mice with MenSCs or their mitochondria, performed morphological analysis of the treated ovaries, and analyzed the changes in the ovarian transcriptome. Treatment with MenSCs or their mitochondria moderately improved the morphology and function of aged ovaries. However, several genes involved in mitochondrial function, particularly ATP biosynthesis were upregulated in aged ovaries treated with MenSCs or their mitochondria. We speculate that the treatment of aged ovaries aged by MenSCs or their mitochondria may restore ovarian function by promoting mitochondrial function, thereby providing a potential therapeutic strategy for improving ovarian reserve and treatment of infertility in elderly women.
Materials and Methods
The major reagents and antibodies used in this study were Collagenase I (Sigma, USA), DMEM (GIBCO, USA), 0.25% Trypsin-EDTA (GIBCO, USA), FITC Anti-CD34 (Ebioscience, USA), FITC Anti-CD45 (Ebioscience, USA), PE Anti-CD29 (Ebioscience, USA), FITC Anti-CD90 (Ebioscience, USA), PE Anti-CD73 (Ebioscience, USA).
Experiments involving animals were approved by the General Hospital Animal Ethics Committee of PLA and were performed in accordance with the NIH Guidelines on the Care and Use of Laboratory Animals. Female CD-1 (ICR) mice aged 10–12 months were used as donors and recipients in the experiment.
Isolation of MenSCs
For preparation of MenSCs, 10–12 months CD-1 (ICR) female mice were sacrificed for cervical dissection, and the bilateral uterus was isolated under aseptic conditions. The fat tissue and blood vessels surrounding the uterine horn were removed and the uterus washed with PBS. The uterus was then cut longitudinally along the uterine cavity to expose the endometrium under microscope, and the endometrium was carefully isolated at 4° C. The tissues were minced and digested for 30–60 minutes with gentle agitation in serum-free medium using 0.1% type I collagenase (Sigma, USA). Then, the enzyme was inactivated and a 200-μm mesh filter was used to the filter samples. The filtered samples were centrifuged at 1200rpm for 5 minutes to pellet the cells. The isolated cells were cultured in DEME low-glucose medium with 10% FBS, 50 U/mL penicillin, and 50 μg/mL streptomycin in a humidified incubator at 37° C with 5% CO2 . To ensure the purity of the MenSCs, we identified MenSCs by flow cytometry (Supplementary Figure 1).
Isolation of mitochondria
Mitochondria were isolated from MenSCs by differential centrifugation. The MenSCs were suspended in PBS at 106 cells per mL. Then the cells were homogenized 4–6 times on ice using a cell homogenizer. The homogenate was then centrifuged for 20 min at 2000 rpm, the supernatant was collected and again centrifuged for 20 min at 10000 rpm for the mitochondria to sediment . All the processes were carried out at 4° C, and the extracts were maintained at 4° C until use.
Preparation of MenSCs 3D alginate gel and mitochondrial 3D alginate gel
The preparation alginate gel was performed as described previously [27, 28]. Sodium alginate powder (Sigma-Aldrich, USA) was dissolved in PBS to form 2% sodium alginate solution at room temperature. The MenSCs were digested with 0.25% trypsin and added into the alginate solution, the cell concentration was adjusted to 106 cells per mL. Then, the cell suspension droplets were added into 1% calcium chloride solution to form a 3D stem cell gelatinous substance. Similarly, we extract mitochondria from 106 stem cells to prepare 3D mitochondria gel. The whole encapsulation process is carried out under aseptic conditions.
Preparation of fluorescent labeled MenSCs
Cultured MenSCs were incubated with 4 μL/mL of CM-Dil and incubated for 30 min at 37° C, shaken once every 10 minutes. After incubation, the cells were washed twice with PBS to remove the excess dye [29, 30].
Treatment of MenSCs gel and MITO gel to the ovaries of recipient mice
Recipient mice (10–12 months old) were individually anesthetized with 0.2 mL of pentobarbital (0.2%). After the mice were anesthetized, they were placed flat on their abdomen, fixed and the dorsal side of the abdomen was disinfected with 75% alcohol. Incision was made to cut the skin and muscle to expose the ovaries. 20–50 μL of control gel, MenSCs gel, or mitochondrial gel was applied it around both ovaries After surgery, the mice were injected with 100,000 U of penicillin to prevent infection. Three recipient mice were used in each of the control and MO-MenSCs and MO-MITO treatment groups.
Morphological examination of mouse ovaries
Seven days after treatment with the control or MenSCs or MITO 3D gel, both ovaries of the recipient mice were isolated and fixed in 4% paraformaldehyde overnight. Following fixation, the ovaries were dehydrated and embedded in paraffin blocks and sections were immobilized on slides. Ovarian sections were stained with hematoxylin and eosin. The CM-Dil red fluorescence of mesenchymal stem cells in the treated ovaries were also imaged within the paraffin section under a fluorescence microscope.
RNA library preparation and sequencing
Ovary samples were homogenized in TRIzol (Invitrogen) and processed according to the manufacturer’s instructions. 2 ug of total RNA from each sample was processed using the NEBNext®Ultra II kit (New England Biolabs, Inc.) according to the manufacturer's instructions. Briefly, mRNAs were captured with oligo-dT magnetic beads and fragmented for 6 min at 94° C. First strand synthesis was performed on fragmented RNA, followed by second strand synthesis and dA-tailing. Adapter ligation was performed using KAPA single-indexed adapters (KAPA, Pleasanton, CA). The adapter-ligated fragments were amplified with 10 PCR cycles. Final libraries were then pooled and sequenced on a HiSeq4000 single-end 50 nt system (Illumina).
RNA-seq data analysis
FASTQ sequence files from biological replicates were concatenated and aligned to the M. musculus reference genome (mm10) using Hisat2 . FeatureCounts software was used for counting reads to each exon or each gene for read summarization . Differentially expressed genes with two-fold or higher change, and p < 0.05 (unpaired t-test) were identified using the DESeq2 program . Enrichment analysis of differentially expressed genes was performed using the web-based software DAVID and including the cellular component Gene Ontology vocabulary. Statistical parameters to consider significant enrichment were p < 0.01, and fold enrichment > 2.
Qi Zhang, Chunlei Liu, Ling Yu, Xiaona Wang and Jianxiu Hao undertook experiments; Xiaona Wang and Jianxiu Hao undertook data analysis; Qi Zhang, Chunlei Liu, Xiaona Wang and Jianxiu Hao undertook interpretation and manuscript preparation; Xiaona Wang and Jianxiu Hao undertook design, interpretation and authored the manuscript.
We are grateful for technical assistance from Mr. Yu Zhu and Xin Li.
Conflicts of Interest
There are no conflicts of interest.
This work was supported by the National Natural Science Foundation of China (No.81801529).
- 1. Nybo Andersen AM, Wohlfahrt J, Christens P, Olsen J, Melbye M. Maternal age and fetal loss: population based register linkage study. BMJ. 2000; 320:1708–12. https://doi.org/10.1136/bmj.320.7251.1708 [PubMed]
- 2. Crawford NM, Steiner AZ. Age-related infertility. Obstet Gynecol Clin North Am. 2015; 42:15–25. https://doi.org/10.1016/j.ogc.2014.09.005 [PubMed]
- 3. te Velde ER, Pearson PL. The variability of female reproductive ageing. Hum Reprod Update. 2002; 8:141–54. https://doi.org/10.1093/humupd/8.2.141 [PubMed]
- 4. Lew R. Natural history of ovarian function including assessment of ovarian reserve and premature ovarian failure. Best Pract Res Clin Obstet Gynaecol. 2019; 55:2–13. https://doi.org/10.1016/j.bpobgyn.2018.05.005 [PubMed]
- 5. Practice Committee of the American Society for Reproductive Medicine. Electronic address: firstname.lastname@example.org, and Practice Committee of the American Society for Reproductive Medicine. Testing and interpreting measures of ovarian reserve: a committee opinion. Fertil Steril. 2020; 114:1151–7. https://doi.org/10.1016/j.fertnstert.2020.09.134 [PubMed]
- 6. van Rooij IA, Broekmans FJ, Scheffer GJ, Looman CW, Habbema JD, de Jong FH, Fauser BJ, Themmen AP, te Velde ER. Serum antimullerian hormone levels best reflect the reproductive decline with age in normal women with proven fertility: a longitudinal study. Fertil Steril. 2005; 83:979–87. https://doi.org/10.1016/j.fertnstert.2004.11.029 [PubMed]
- 7. Donnez J, Dolmans MM. Natural hormone replacement therapy with a functioning ovary after the menopause: dream or reality? Reprod Biomed Online. 2018; 37:359–66. https://doi.org/10.1016/j.rbmo.2018.05.018 [PubMed]
- 8. Laronda MM, Rutz AL, Xiao S, Whelan KA, Duncan FE, Roth EW, Woodruff TK, Shah RN. A bioprosthetic ovary created using 3D printed microporous scaffolds restores ovarian function in sterilized mice. Nat Commun. 2017; 8:15261. https://doi.org/10.1038/ncomms15261 [PubMed]
- 9. Bahrehbar K, Rezazadeh Valojerdi M, Esfandiari F, Fathi R, Hassani SN, Baharvand H. Human embryonic stem cell-derived mesenchymal stem cells improved premature ovarian failure. World J Stem Cells. 2020; 12:857–78. https://doi.org/10.4252/wjsc.v12.i8.857 [PubMed]
- 10. Wang Z, Wang Y, Yang T, Li J, Yang X. Study of the reparative effects of menstrual-derived stem cells on premature ovarian failure in mice. Stem Cell Res Ther. 2017; 8:11. https://doi.org/10.1186/s13287-016-0458-1 [PubMed]
- 11. Murphy KC, Whitehead J, Falahee PC, Zhou D, Simon SI, Leach JK. Multifactorial Experimental Design to Optimize the Anti-Inflammatory and Proangiogenic Potential of Mesenchymal Stem Cell Spheroids. Stem Cells. 2017; 35:1493–504. https://doi.org/10.1002/stem.2606 [PubMed]
- 12. Chen L, Qu J, Cheng T, Chen X, Xiang C. Menstrual blood-derived stem cells: toward therapeutic mechanisms, novel strategies, and future perspectives in the treatment of diseases. Stem Cell Res Ther. 2019; 10:406. https://doi.org/10.1186/s13287-019-1503-7 [PubMed]
- 13. Manley H, Sprinks J, Breedon P. Menstrual Blood-Derived Mesenchymal Stem Cells: Women’s Attitudes, Willingness, and Barriers to Donation of Menstrual Blood. J Womens Health (Larchmt). 2019; 28:1688–97. https://doi.org/10.1089/jwh.2019.7745 [PubMed]
- 14. Chen L, Qu J, Xiang C. The multi-functional roles of menstrual blood-derived stem cells in regenerative medicine. Stem Cell Res Ther. 2019; 10:1. https://doi.org/10.1186/s13287-018-1105-9 [PubMed]
- 15. Tan J, Li P, Wang Q, Li Y, Li X, Zhao D, Xu X, Kong L. Autologous menstrual blood-derived stromal cells transplantation for severe Asherman’s syndrome. Hum Reprod. 2016; 31:2723–9. https://doi.org/10.1093/humrep/dew235 [PubMed]
- 16. Bentov Y, Yavorska T, Esfandiari N, Jurisicova A, Casper RF. The contribution of mitochondrial function to reproductive aging. J Assist Reprod Genet. 2011; 28:773–83. https://doi.org/10.1007/s10815-011-9588-7 [PubMed]
- 17. May-Panloup P, Boucret L, Chao de la Barca JM, Desquiret-Dumas V, Ferré-L’Hotellier V, Morinière C, Descamps P, Procaccio V, Reynier P. Ovarian ageing: the role of mitochondria in oocytes and follicles. Hum Reprod Update. 2016; 22:725–43. https://doi.org/10.1093/humupd/dmw028 [PubMed]
- 18. Aiken CE, Tarry-Adkins JL, Penfold NC, Dearden L, Ozanne SE. Decreased ovarian reserve, dysregulation of mitochondrial biogenesis, and increased lipid peroxidation in female mouse offspring exposed to an obesogenic maternal diet. FASEB J. 2016; 30:1548–56. https://doi.org/10.1096/fj.15-280800 [PubMed]
- 19. Perez GI, Trbovich AM, Gosden RG, Tilly JL. Mitochondria and the death of oocytes. Nature. 2000; 403:500–1. https://doi.org/10.1038/35000651 [PubMed]
- 20. Hamatani T, Falco G, Carter MG, Akutsu H, Stagg CA, Sharov AA, Dudekula DB, VanBuren V, Ko MS. Age-associated alteration of gene expression patterns in mouse oocytes. Hum Mol Genet. 2004; 13:2263–78. https://doi.org/10.1093/hmg/ddh241 [PubMed]
- 21. Dumollard R, Duchen M, Carroll J. The role of mitochondrial function in the oocyte and embryo. Curr Top Dev Biol. 2007; 77:21–49. https://doi.org/10.1016/S0070-2153(06)77002-8 [PubMed]
- 22. Zhao XM, Min JT, Du WH, Hao HS, Liu Y, Qin T, Wang D, Zhu HB. Melatonin enhances the in vitro maturation and developmental potential of bovine oocytes denuded of the cumulus oophorus. Zygote. 2015; 23:525–36. https://doi.org/10.1017/S0967199414000161 [PubMed]
- 23. Anderson S, Bankier AT, Barrell BG, de Bruijn MH, Coulson AR, Drouin J, Eperon IC, Nierlich DP, Roe BA, Sanger F, Schreier PH, Smith AJ, Staden R, Young IG. Sequence and organization of the human mitochondrial genome. Nature. 1981; 290:457–65. https://doi.org/10.1038/290457a0 [PubMed]
- 24. da Fonseca RR, Johnson WE, O’Brien SJ, Ramos MJ, Antunes A. The adaptive evolution of the mammalian mitochondrial genome. BMC Genomics. 2008; 9:119. https://doi.org/10.1186/1471-2164-9-119 [PubMed]
- 25. Mastrorocco A, Cacopardo L, Martino NA, Fanelli D, Camillo F, Ciani E, Roelen BAJ, Ahluwalia A, Dell’Aquila ME. One-step automated bioprinting-based method for cumulus-oocyte complex microencapsulation for 3D in vitro maturation. PLoS One. 2020; 15:e0238812. https://doi.org/10.1371/journal.pone.0238812 [PubMed]
- 26. Wang ZB, Hao JX, Meng TG, Guo L, Dong MZ, Fan LH, Ouyang YC, Wang G, Sun QY, Ou XH, Yao YQ. Transfer of autologous mitochondria from adipose tissue-derived stem cells rescues oocyte quality and infertility in aged mice. Aging (Albany NY). 2017; 9:2480–8. https://doi.org/10.18632/aging.101332 [PubMed]
- 27. Lv K, Li Q, Zhang L, Wang Y, Zhong Z, Zhao J, Lin X, Wang J, Zhu K, Xiao C, Ke C, Zhong S, Wu X, et al. Incorporation of small extracellular vesicles in sodium alginate hydrogel as a novel therapeutic strategy for myocardial infarction. Theranostics. 2019; 9:7403–16. https://doi.org/10.7150/thno.32637 [PubMed]
- 28. Sidhu K, Kim J, Chayosumrit M, Dean S, Sachdev P. Alginate microcapsule as a 3D platform for propagation and differentiation of human embryonic stem cells (hESC) to different lineages. J Vis Exp. 2012; 61:e3608. https://doi.org/10.3791/3608 [PubMed]
- 29. Jalalie L, Rezaie MJ, Jalili A, Rezaee MA, Vahabzadeh Z, Rahmani MR, Karimipoor M, Hakhamaneshi MS. Distribution of the CM-Dil-Labeled Human Umbilical Cord Vein Mesenchymal Stem Cells Migrated to the Cyclophosphamide-Injured Ovaries in C57BL/6 Mice. Iran Biomed J. 2019; 23:200–8. https://doi.org/10.29252/.23.3.200 [PubMed]
- 30. Zheng JH, Zhang JK, Kong DS, Song YB, Zhao SD, Qi WB, Li YN, Zhang ML, Huang XH. Quantification of the CM-Dil-labeled human umbilical cord mesenchymal stem cells migrated to the dual injured uterus in SD rat. Stem Cell Res Ther. 2020; 11:280. https://doi.org/10.1186/s13287-020-01806-4 [PubMed]
- 31. Kim D, Langmead B, Salzberg SL. HISAT: a fast spliced aligner with low memory requirements. Nat Methods. 2015; 12:357–60. https://doi.org/10.1038/nmeth.3317 [PubMed]
- 32. Liao Y, Smyth GK, Shi W. featureCounts: an efficient general purpose program for assigning sequence reads to genomic features. Bioinformatics. 2014; 30:923–30. https://doi.org/10.1093/bioinformatics/btt656 [PubMed]
- 33. Varet H, Brillet-Guéguen L, Coppée JY, Dillies MA. SARTools: A DESeq2- and EdgeR-Based R Pipeline for Comprehensive Differential Analysis of RNA-Seq Data. PLoS One. 2016; 11:e0157022. https://doi.org/10.1371/journal.pone.0157022 [PubMed]